AUS
NZ
UK
CA
USA
IND
Healthcare
Telix Pharmaceuticals Strengthens Oncology Pipeline Within ASX 200
February 27, 2026 03:01 PM AEDT| By SamTelix Pharmaceuticals expands its radiopharmaceutical portfolio, combining commercial imaging revenue with an advancing oncology therapy pipeline.
How a Smart Funding Path Is Reshaping Innovation on the ASX Stock Market
February 27, 2026 12:02 PM AEDT| By SamFlexible funding models and research incentives are reshaping how healthcare innovators plan, develop, and sustain long-term scientific progress on the Australian share market.
Global Obesity Drug Race Sends Signals to the ASX Market
February 27, 2026 11:48 AM AEDT| By SamGlobal obesity drug innovation is intensifying, with delivery design and clinical confidence shaping leadership, while Australian healthcare markets continue to track these international signals closely.
Is IMU Drawing Fresh Attention in the All Ordinaries Ahead of Key US Data Reveal?
February 27, 2026 11:42 AM AEDT| By SamImugene will present Azer-Cel clinical data at a major US healthcare conference, reinforcing biotechnology visibility within the All Ordinaries index.
ASX Market Update: Is Lumos Building Momentum in the ASX All Ords Healthcare Segment?
February 27, 2026 11:42 AM AEDT| By SamLumos improved operating cash flow on FebriDx momentum while reporting a wider first-half loss within the ASX All Ords healthcare segment.
Anteris Advances Clinical Program Within the All Ordinaries Healthcare Segment
February 27, 2026 11:34 AM AEDT| By SamAnteris reports operating cash outflow as the Paradigm clinical trial advances, highlighting structural heart innovation within the All Ordinaries healthcare sector.
Why This asx 200 Healthcare Leader Is Shaping Long-Term Market Confidence
February 27, 2026 11:30 AM AEDT| By SamA deep dive into how an Australian healthcare leader leverages innovation, global demand, and structural health trends to maintain relevance within major equity benchmarks.
CSL Share Price in Focus as Buyback and Dividend Near
February 26, 2026 10:47 PM AEDT| By SamCSL’s share price remains under focus as buyback activity continues and dividend dates approach, while investors assess sector momentum and operational updates within Australia’s healthcare landscape.
Cochlear Valuation in Focus After Earnings Update
February 26, 2026 05:56 PM AEDT| By SamCochlear’s latest results spark renewed valuation debate as investors weigh innovation strength, dividend stability and contrasting fair value models within the Australian healthcare landscape.
Telix Pharmaceuticals (ASX:TLX) Rises on Sales Guidance in ASX 200
February 26, 2026 04:03 PM AEDT| By SamTelix Pharmaceuticals in the ASX 200 outlines higher revenue guidance, shelf registration plans, and glioma imaging expansion, highlighting evolving radiopharmaceutical and oncology platform development.
Superloop (ASX:SLC) Joins ASX 300 After Revenue Earnings Gain
February 26, 2026 03:58 PM AEDT| By SamSuperloop’s ASX 300 performance highlights revenue growth, earnings recovery, broadband scale expansion, and competitive telecom positioning across consumer and enterprise markets.
Telix Pharmaceuticals Momentum Reflects Healthcare Interest on ASX 200
February 26, 2026 01:23 PM AEDT| By SamTelix Pharmaceuticals draws investor attention within the ASX 200 healthcare sector as trading activity reflects developments in radiopharmaceutical innovation.
Control Bionics Expands US AAC Operations Across All Ordinaries
February 26, 2026 12:09 PM AEDT| By SamControl Bionics enhances US operational control through a revised joint venture, advancing its AAC technology presence within the All Ordinaries healthcare segment.
Is Pro Medicus Holding Premium Valuation Strength Within the ASX 200 Healthcare Space?
February 25, 2026 07:31 PM AEDT| By SamPro Medicus reported strong half-year performance with recurring revenue momentum, drawing valuation focus within the ASX 200 healthcare sector.
Pro Medicus Share Price Under Pressure Ahead of Dividend
February 24, 2026 07:47 PM AEDT| By SamPro Medicus share price retreats amid ASX tech selloff as dividend date approaches, while broader market stability and sector rotation shape investor sentiment.
Pro Medicus Shares in Focus: Key Metrics to Track
February 24, 2026 05:57 PM AEDT| By SamA detailed look at Pro Medicus Ltd (ASX:PME), exploring revenue growth, margins, balance sheet health, and return metrics shaping its valuation outlook within Australia’s healthcare technology sector.
ASX 200 Watchlist: Why Nanosonics Is Drawing Market Focus
February 24, 2026 04:35 PM AEDT| By SamHealthcare technology stocks are gaining structural relevance as hospital modernisation, automation, and safety infrastructure reshape capital flows across the Australian equity market.
Regis Healthcare Advances Across ASX 200 After Funding Expansion Update
February 24, 2026 02:04 PM AEDT| By SamRegis Healthcare (ASX:REG) expanded funding arrangements, strengthening its capital structure within the ASX 200 and ASX 300 healthcare sector.
All Ords Healthcare Spotlight on Orthocell’s (ASX:OCC) Commercial Progress
February 24, 2026 12:20 PM AEDT| By SamOrthocell (ASX:OCC) reported record half-year revenue as US rollout efforts expand within the ASX All Ords healthcare sector.
A New Chapter for Precision Oncology on the ASX
February 24, 2026 12:08 PM AEDT| By SamClarity Pharmaceuticals draws market attention as clinical progress reinforces confidence in precision oncology and highlights the evolving role of biotechnology within Australia’s listed healthcare landscape.
Advertise your brand on Kalkine Media